Panelists discuss how managing oral therapy toxicities requires preemptive planning, multidisciplinary team involvement, ...

Patients seeking access to oral acute myeloid leukemia (AML) medications face complex insurance approval processes that can ...

The FDA’s Office of Prescription Drug Promotion (OPDP) issued an Untitled Letter, backdated to September 23, to Tracey M. Henderson, MS, MBA – AstraZeneca’s promotional regulatory affairs review ...